Pharmaxis Ltd ( (AU:SNT) ) has issued an update.
Syntara Limited announced that its abstract on SNT-5505, a treatment for myelofibrosis, has been selected for a poster presentation at the European Hematology Association 2025 Congress. This recognition underscores the growing potential of SNT-5505, especially following positive early data, and aligns with the company’s strategy to present new data to shareholders and the scientific community. The presentation is expected to enhance peer review opportunities and further position Syntara as a key player in the hematology field.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company focusing on extracellular matrix dysfunction, utilizing expertise in amine oxidase chemistry to create novel medicines for blood cancers and conditions related to inflammation and fibrosis. Their lead candidate, SNT-5505, targets myelofibrosis, a bone marrow cancer, and has received FDA Orphan Drug Designation. Syntara is also involved in developing treatments for other fibrotic and inflammatory diseases and has previously developed and sold two respiratory products.
YTD Price Performance: -32.50%
Average Trading Volume: 3,520,372
Technical Sentiment Signal: Buy
Current Market Cap: A$87.71M
See more insights into SNT stock on TipRanks’ Stock Analysis page.